Avinger (AVGR) Tops Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Avinger, Inc. Announces Second Quarter 2015 Results
July 28, 2015 4:02 PM EDTAchieved Positive 30-Day Results for Clinical Trial for Pantheris
Expanded Installed Base of Company's Lumivascular Platform
REDWOOD CITY, Calif., July 28, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ: AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today reported results for the second quarter ended June 30, 2015.
Recent Highlights
Surpassed primary efficacy endpoint performance goal in 30-day data from VISION Trial. Results demonstrated that... MoreAvinger, Inc. Announces Second Quarter 2015 Results
July 28, 2015 4:02 PM EDTAchieved Positive 30-Day Results for Clinical Trial for Pantheris
Expanded Installed Base of Company's Lumivascular Platform
REDWOOD CITY, Calif., July 28, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ: AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today reported results for the second quarter ended June 30, 2015.
Recent Highlights
Surpassed primary efficacy endpoint performance goal in 30-day data from VISION Trial. Results demonstrated that... More